- 首頁(yè)
- 科研細(xì)胞
- 藥靶模型
-
診斷試劑
腫瘤早篩甲基化標(biāo)準(zhǔn)品
遺傳性基因標(biāo)準(zhǔn)品
優(yōu)生優(yōu)育標(biāo)準(zhǔn)品
HLA標(biāo)準(zhǔn)品
數(shù)字PCR
- 技術(shù)服務(wù)
- 新聞中心
- 資源中心
- 關(guān)于我們
- 聯(lián)系我們
診斷試劑
diagnosis
I. Background | |||||||||||||||||||||||||||||||||||
Tumor mutational burden (TMB) shows great promise as a biomarker for immuno-oncology (I-O) therapy response, but progress is hindered by the lack of a standardized TMB measurement by targeted NGS panels, and an absence of TMB reference materials.
|
相關(guān)產(chǎn)品推薦
下一篇:tTMB-P2(9.84) Reference Standard
返回列表